Pediatric Arthritis Study of Certolizumab Pegol
Public ClinicalTrials.gov record NCT01550003. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
Study identification
- NCT ID
- NCT01550003
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 193 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 2 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 8, 2012 (Actual)
- Primary completion
- Apr 8, 2024 (Actual)
- Completion
- Apr 8, 2024 (Actual)
- Last update posted
- Sep 25, 2026
2012 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ra0043 71 | Little Rock | Arkansas | 72202 | — |
| Ra0043 79 | Los Angeles | California | 90027-6062 | — |
| Ra0043 84 | San Francisco | California | 94143 | — |
| Ra0043 83 | Hartford | Connecticut | 06106 | — |
| Ra0043 81 | Washington D.C. | District of Columbia | 20010 | — |
| Ra0043 82 | Chicago | Illinois | 60611 | — |
| Ra0043 90 | Chicago | Illinois | 60637 | — |
| Ra0043 75 | Indianapolis | Indiana | 46202 | — |
| Ra0043 80 | Hackensack | New Jersey | 07601 | — |
| Ra0043 77 | Livingston | New Jersey | 07039 | — |
| Ra0043 85 | New Hyde Park | New York | 11042 | — |
| Ra0043 87 | New York | New York | 10032 | — |
| Ra0043 74 | Charlotte | North Carolina | 28203 | — |
| Ra0043 76 | Durham | North Carolina | 27710 | — |
| Ra0043 70 | Avon | Ohio | 44011 | — |
| Ra0043 73 | Cincinnati | Ohio | 45229 | — |
| Ra0043 78 | Cleveland | Ohio | 44109 | — |
| Ra0043 95 | Cleveland | Ohio | 44195 | — |
| Ra0043 86 | Columbus | Ohio | 43205-2694 | — |
| Ra0043 89 | Portland | Oregon | 97227 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01550003, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01550003 live on ClinicalTrials.gov.